Search ↗

Comparison

Survodutide vs Tirzepatide

Both are GLP-1 & incretins, so the meaningful differences are in kinetics, evidence and regulatory status.

On published evidence alone, Tirzepatide is the better documented of the two (regulator approved). That is a statement about the state of the literature, not a recommendation.

Survodutide Tirzepatide
Class GLP-1 & incretins GLP-1 & incretins
Evidence Clinical trials Regulator approved
Human trials ~6 ~60
Half-life ~6-7 days ~5 days
Reported range 800 mcg - 6 mg 2.5-15 mg
Frequency Once weekly (trial protocols) Once weekly, titrated over 20+ weeks
Routes Subcutaneous Subcutaneous
FDA approved No Yes
Research use only Yes No
Banned in sport No No
Studied for Investigational MASH treatment, Obesity research Type 2 diabetes, Chronic weight management, Obstructive sleep apnoea with obesity
Reported side effects Nausea, Vomiting, Diarrhoea, Increased heart rate Nausea, Diarrhoea, Vomiting, Constipation, Dyspepsia, Injection-site reactions

Survodutide

Survodutide agonises both the glucagon receptor and the GLP-1 receptor, without the GIP activity of tirzepatide. The glucagon component increases energy expenditure and hepatic fat oxidation, which is why its most advanced programme is in metabolic dysfunction-associated steatohepatitis rather than obesity alone. Phase II data reported meaningful improvement in liver fibrosis endpoints alongside weight reduction.

Tirzepatide

Tirzepatide is a 39-amino-acid synthetic peptide that agonises both the glucose-dependent insulinotropic polypeptide receptor and the GLP-1 receptor, a combination sometimes called a twincretin. GIP receptor activity appears to add to the metabolic effect through adipose tissue and central pathways, and may attenuate some GLP-1-related nausea. A C20 fatty diacid moiety confers albumin binding and weekly dosing. The SURMOUNT programme reported mean weight reductions above 20% at the highest dose, and SURMOUNT-5 showed superiority over semaglutide directly.

Survodutide vs Tirzepatide: common questions

What is the difference between Survodutide and Tirzepatide?

Both are GLP-1 & incretins. Survodutide: An investigational dual glucagon and GLP-1 receptor agonist, studied heavily in metabolic liver disease. Tirzepatide: A dual GIP and GLP-1 receptor agonist that produced greater weight loss than semaglutide in head-to-head trial data.

Which has stronger evidence, Survodutide or Tirzepatide?

Tirzepatide has the stronger evidence base (regulator approved, about 60 human studies) compared with Survodutide (clinical trials).

Are Survodutide and Tirzepatide FDA approved?

Only Tirzepatide is FDA approved (Type 2 diabetes mellitus (Mounjaro); Chronic weight management (Zepbound); Moderate to severe obstructive sleep apnoea in adults with obesity). Survodutide is not approved for any indication.

References

Regulatory and primary sources

  1. PubChem compound record (CID 171378821) ↗ · structure, identifiers, synonyms
  2. FDA: Unapproved drugs and "research use only" products ↗ · regulatory status of non-approved products
  3. PubChem compound record (CID 156588324) ↗ · structure, identifiers, synonyms
  4. DailyMed: FDA-approved labeling for Tirzepatide ↗ · indications, dosing, warnings as approved
  5. FDA Drugs@FDA database ↗ · approval history
  6. CAS Registry Number 2023788-19-2 ↗ · chemical identity

Published literature

  1. Sanyal AJ, Bedossa P, Fraessdorf M, et al.. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.N Engl J Med 2024.PubMed 38847460 · doi:10.1056/NEJMoa2401755
  2. Sinha B, Ghosal S. Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.Obesity (Silver Spring) 2025.PubMed 40685589 · doi:10.1002/oby.24360
  3. Drucker DJ. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.Diabetes Care 2024.PubMed 38843460 · doi:10.2337/dci24-0003
  4. le Roux CW, Steen O, Lucas KJ, et al.. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.Lancet Diabetes Endocrinol 2024.PubMed 38330987 · doi:10.1016/S2213-8587(23)00356-X
  5. Newsome PN, Loomba R. Therapeutic horizons in metabolic dysfunction-associated steatohepatitis.J Clin Invest 2025.PubMed 40590228 · doi:10.1172/JCI186425
  6. Kokkorakis M, Chakhtoura M, Rhayem C, et al.. Emerging pharmacotherapies for obesity: A systematic review.Pharmacol Rev 2025.PubMed 39952695 · doi:10.1124/pharmrev.123.001045
  7. Souza M, Al-Sharif L, Antunes VLJ, et al.. Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.Hepatology 2025.PubMed 39903735 · doi:10.1097/HEP.0000000000001254
  8. Singh A, Sohal A, Batta A. GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis.World J Gastroenterol 2024.PubMed 39735270 · doi:10.3748/wjg.v30.i48.5205
  9. Jastreboff AM, le Roux CW, Stefanski A, et al.. Tirzepatide for Obesity Treatment and Diabetes Prevention.N Engl J Med 2025.PubMed 39536238 · doi:10.1056/NEJMoa2410819
  10. Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide Once Weekly for the Treatment of Obesity.N Engl J Med 2022.PubMed 35658024 · doi:10.1056/NEJMoa2206038
  11. Aronne LJ, Sattar N, Horn DB, et al.. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.JAMA 2024.PubMed 38078870 · doi:10.1001/jama.2023.24945
  12. Malhotra A, Grunstein RR, Fietze I, et al.. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.N Engl J Med 2024.PubMed 38912654 · doi:10.1056/NEJMoa2404881
  13. Packer M, Zile MR, Kramer CM, et al.. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.N Engl J Med 2025.PubMed 39555826 · doi:10.1056/NEJMoa2410027
  14. Aronne LJ, Horn DB, le Roux CW, et al.. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.N Engl J Med 2025.PubMed 40353578 · doi:10.1056/NEJMoa2416394
  15. Look M, Dunn JP, Kushner RF, et al.. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.Diabetes Obes Metab 2025.PubMed 39996356 · doi:10.1111/dom.16275
  16. Frías JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.N Engl J Med 2021.PubMed 34170647 · doi:10.1056/NEJMoa2107519

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.